Trial Profile
A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 14 Apr 2022
Price :
$35
*
At a glance
- Drugs Cariprazine (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors AbbVie; Allergan; Forest Laboratories
- 07 Jul 2021 This trial has been completed in Bulgaria, according to European Clinical Trials Database
- 16 Jun 2021 Status changed from active, no longer recruiting to discontinued ( the study was stopped: FDA Released Allergan from it's post marketing requirement)
- 11 Jan 2021 Status changed from recruiting to active, no longer recruiting.